Pzena Investment Management LLC Reduces Position in Globe Life Inc. $GL

Pzena Investment Management LLC lessened its holdings in shares of Globe Life Inc. (NYSE:GL) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 976,047 shares of the company’s stock after selling 22,459 shares during the period. Pzena Investment Management LLC’s holdings in Globe Life were worth $136,510,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Leonteq Securities AG purchased a new stake in Globe Life during the 4th quarter valued at about $161,000. Handelsbanken Fonder AB grew its stake in Globe Life by 23.1% during the 4th quarter. Handelsbanken Fonder AB now owns 75,235 shares of the company’s stock valued at $10,522,000 after acquiring an additional 14,135 shares in the last quarter. Resona Asset Management Co. Ltd. grew its stake in Globe Life by 15.3% during the 4th quarter. Resona Asset Management Co. Ltd. now owns 1,008 shares of the company’s stock valued at $143,000 after acquiring an additional 134 shares in the last quarter. ProShare Advisors LLC grew its stake in Globe Life by 2.6% during the 4th quarter. ProShare Advisors LLC now owns 17,216 shares of the company’s stock valued at $2,408,000 after acquiring an additional 439 shares in the last quarter. Finally, HighTower Advisors LLC grew its stake in Globe Life by 1.5% during the 4th quarter. HighTower Advisors LLC now owns 15,173 shares of the company’s stock valued at $2,122,000 after acquiring an additional 226 shares in the last quarter. Hedge funds and other institutional investors own 81.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Texas Capital upgraded shares of Globe Life to a “strong-buy” rating in a report on Wednesday, March 18th. Wells Fargo & Company boosted their target price on shares of Globe Life from $171.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Keefe, Bruyette & Woods reiterated a “moderate buy” rating and issued a $168.00 target price on shares of Globe Life in a report on Thursday, March 26th. Weiss Ratings upgraded shares of Globe Life from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 13th. Finally, Morgan Stanley boosted their target price on shares of Globe Life from $176.00 to $181.00 and gave the company an “overweight” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $173.22.

Insider Buying and Selling at Globe Life

In other Globe Life news, CFO Thomas Peter Kalmbach sold 11,903 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $156.61, for a total transaction of $1,864,128.83. Following the sale, the chief financial officer directly owned 48,432 shares in the company, valued at $7,584,935.52. This represents a 19.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Edward Hensley sold 712 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $142.59, for a total transaction of $101,524.08. Following the sale, the executive vice president owned 8,580 shares in the company, valued at approximately $1,223,422.20. This trade represents a 7.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 106,550 shares of company stock valued at $16,140,745 in the last quarter. Corporate insiders own 2.11% of the company’s stock.

Globe Life Stock Performance

Shares of GL stock opened at $156.45 on Friday. The firm’s 50 day moving average price is $146.93 and its 200-day moving average price is $141.81. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.07 and a current ratio of 0.07. Globe Life Inc. has a one year low of $116.73 and a one year high of $157.92. The firm has a market cap of $12.15 billion, a P/E ratio of 10.82 and a beta of 0.50.

Globe Life (NYSE:GL) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $3.43 EPS for the quarter, missing the consensus estimate of $3.46 by ($0.03). The company had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.56 billion. Globe Life had a return on equity of 20.94% and a net margin of 19.38%.The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.07 earnings per share. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS. As a group, equities research analysts predict that Globe Life Inc. will post 15.56 EPS for the current year.

Globe Life Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Monday, July 6th will be issued a dividend of $0.33 per share. The ex-dividend date is Monday, July 6th. This represents a $1.32 dividend on an annualized basis and a yield of 0.8%. Globe Life’s dividend payout ratio is 9.13%.

Globe Life Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.